Cargando…

Therapeutic options and challenges for substances of abuse

Addiction to substances continues to be a significant public health concern in the United States. The following review of current pharmacological treatments discusses a range of substances: nicotine, alcohol, cocaine, and opioids. The goal is to provide an overview of currently available and new pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardner, Tracie J., Kosten, Thomas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Les Laboratoires Servier 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202509/
https://www.ncbi.nlm.nih.gov/pubmed/18286802
_version_ 1782215002003865600
author Gardner, Tracie J.
Kosten, Thomas R.
author_facet Gardner, Tracie J.
Kosten, Thomas R.
author_sort Gardner, Tracie J.
collection PubMed
description Addiction to substances continues to be a significant public health concern in the United States. The following review of current pharmacological treatments discusses a range of substances: nicotine, alcohol, cocaine, and opioids. The goal is to provide an overview of currently available and new pharmacological treatments for substance use disorders, while also addressing the pharmacothera-peutic challenges remaining. The significant advances in pharmacotherapy have had limited utilization, however. For example, naltrexone for alcoholism is infrequently prescribed, buprenorphine for opiates still has relatively few qualified prescribers, and stimulants have no Food and Drug Administration-approved pharmacotherapy. These pharmacotherapies are needed, with the rate of even the relatively uncommon abuse of opiates now rising sharply.
format Online
Article
Text
id pubmed-3202509
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Les Laboratoires Servier
record_format MEDLINE/PubMed
spelling pubmed-32025092011-10-27 Therapeutic options and challenges for substances of abuse Gardner, Tracie J. Kosten, Thomas R. Dialogues Clin Neurosci Pharmacological Aspects Addiction to substances continues to be a significant public health concern in the United States. The following review of current pharmacological treatments discusses a range of substances: nicotine, alcohol, cocaine, and opioids. The goal is to provide an overview of currently available and new pharmacological treatments for substance use disorders, while also addressing the pharmacothera-peutic challenges remaining. The significant advances in pharmacotherapy have had limited utilization, however. For example, naltrexone for alcoholism is infrequently prescribed, buprenorphine for opiates still has relatively few qualified prescribers, and stimulants have no Food and Drug Administration-approved pharmacotherapy. These pharmacotherapies are needed, with the rate of even the relatively uncommon abuse of opiates now rising sharply. Les Laboratoires Servier 2007-12 /pmc/articles/PMC3202509/ /pubmed/18286802 Text en Copyright: © 2007 LLS http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pharmacological Aspects
Gardner, Tracie J.
Kosten, Thomas R.
Therapeutic options and challenges for substances of abuse
title Therapeutic options and challenges for substances of abuse
title_full Therapeutic options and challenges for substances of abuse
title_fullStr Therapeutic options and challenges for substances of abuse
title_full_unstemmed Therapeutic options and challenges for substances of abuse
title_short Therapeutic options and challenges for substances of abuse
title_sort therapeutic options and challenges for substances of abuse
topic Pharmacological Aspects
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202509/
https://www.ncbi.nlm.nih.gov/pubmed/18286802
work_keys_str_mv AT gardnertraciej therapeuticoptionsandchallengesforsubstancesofabuse
AT kostenthomasr therapeuticoptionsandchallengesforsubstancesofabuse